Navigation Links
NT-proBNP is a predictor of CV risk in arthritis patients taking NSAIDs
Date:6/17/2010

Rome, Italy, Thursday 17 June 2010: The role of N-terminal pro-B-type natriuretic peptide (NT-proBNP, a protein thought to be a regulator of cardiovascular function) as a robust, non-invasive predictor of cardiovascular (CV) risk in patients with arthritis taking cyclooxygenase inhibitors has been reinforced by the results of a multinational study presented today at EULAR 2010, the Annual Congress of the European League Against Rheumatism in Rome, Italy.

The presence of NT-proBNP was associated with a range of CV outcomes, including CV death (p= < 0.0001), myocardial infarction (MI) (p=0.02), heart failure (HF) (p=0.004) and a composite of thrombotic events (CV death, MI, or stroke) (p= < 0.0001). This marker for CV risk remained strongly predictive of CV events after adjustment for age, sex, diabetes, hypertension, type of arthritis, body mass index (BMI), renal function and history of prior CV disease. The results of this multinational trial, which involved The Thrombolysis in Myocardial Infarction (TIMI) Study Group, evaluated 2-year CV outcomes in 6,273 patients with rheumatoid arthritis (RA) and osteoarthritis treated with the non-steroidal anti-inflammatory treatments etoricoxib or diclofenac.

"This study has validated previous research showing that NT-proBNP is a strong indicator for cardiovascular risk in arthritis patients," said Professor Kay Brune, lead author, Department of Pharmacology, University of Erlangen, Erlangen, Germany. "This means that clinically, the presence of NT-proBNP can be used to accurately assess a patients' CV risk, meaning that appropriate treatment options can be identified early on."

Furthermore, the assessment of CV disease risk in patients with Rheumatoid Arthritis (RA) was studied in a separate 15-year follow-up study of Norwegian patients. The study aimed to determine whether early markers of RA inflammatory disease activity could predict arterial stiffness, a surrogate marker of CV disease. Arterial stiffness was measured as Pulse Wave Velocity (PWV) and Augmentation Index (AIx).

"From this research, we can now say that certain inflammatory markers seem to be independent, longitudinal predictors of CV risk in RA patients. Treatment options that help manage early inflammation in patients with RA may ensure that the long-term CV risk associated with RA is managed appropriately," said Dr. Sella Provan, Diakonhjemmet Hospital, Oslo, Norway, and lead author of the study.

In the Norwegian study, patients with elevated baseline C-reactive protein (CRP, a blood protein, levels of which may rise in response to certain types of inflammation) had a significantly higher AIx Beta co-efficient Confidence Interval (β(CI) 2.67 (0.06-5.31) p=0.045) and PWV after 15 years (β(CI) 0.08 (0.01-0.14) p=0.02) after adjustments for age, sex and mean arterial pressure (MAP). Baseline elevated CRP remained a significant predictor of increased AIx after adjustment for possible current confounders.


'/>"/>

Contact: Rory Berrie
eularpressoffice@uk.cohnwolfe.com
44-790-151-3297
European League Against Rheumatism
Source:Eurekalert

Related medicine news :

1. UBC-Providence health team identifies a key predictor of cardiovascular death
2. Family history is strong predictor of obstructive coronary artery disease using CCTA
3. Plaque on CT scan is strong predictor of heart disease, worse long-term outcomes
4. Researchers receive NIH grant to study predictors and outcomes of autoimmune lung disease
5. Ultrasound measurement of fetal adrenal gland a better predictor of preterm birth
6. Almost three quarters of women with rheumatoid arthritis worldwide suffer pain daily
7. Osteoarthritis Claims Growing Number of Younger Victims
8. Out-of-Pocket Costs Limit Access to Arthritis Drugs
9. Massage Envy Provides Effective Way to Manage Arthritis Pain
10. O2 Media's Hit Morning Show &#8216;The Balancing Act' Welcomes the Arthritis Foundation to the Program
11. Jeffrey Gottfurcht Children's Arthritis Foundation Launches With Mount Everest Climb
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2017)... ... July 25, 2017 , ... Centurion Service Group ... Regional Account Manager for the Northeast and Florida regions. In this role, Jennifer ... obsolete medical assets. , Jennifer joins Centurion with a wealth of knowledge and ...
(Date:7/25/2017)... Texas (PRWEB) , ... July 25, 2017 , ... ... fastest growing ATM provider in the United States, today announced its partnership with ... financial institutions. , The foundation of the solution lies within Hyosung’s superior ...
(Date:7/24/2017)... ... July 24, 2017 , ... Engineers at the University of Maryland have ... same kind of electrical energy that the body uses. , In ordinary batteries ... flow of electrons out of the battery is generated by moving positive ions from ...
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... ... the federal Substance Abuse and Mental Health Services Administration’s (SAMHSA) State Targeted Response ... California Department of Health Care Services, will facilitate the development of a hub ...
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... Every year, ... invigorating and educational conference, InstructureCon. Each annual event is coupled with a dynamic theme ... with a James Bond theme, Mission: InstructureCon 0017. , To extend their partnership ...
Breaking Medicine News(10 mins):
(Date:7/13/2017)... 13, 2017 RK Logistics Group, Inc. was awarded ... for its Fremont, CA headquarters facility ... Tri-Valley and San Jose for hi-tech, ... Fremont , with its Fremont Innovation District, is excited ... a powerful resource to the hundreds of biotech, pharma and ...
(Date:7/12/2017)... ANGELES , July 12, 2017 CarpalAID is a ... drugs, braces or surgery. Carpal tunnel syndrome affects more ... syndrome at twice the rate of men. The common methods of ... or mobilization with uncomfortable hand braces or gloves. ... CarpalAID is a clear ...
(Date:7/11/2017)... , July 11, 2017 Zymo Research Corp., also known ... that can quantify biological aging in a precise manner using the myDNAge ... Steve Horvath , a professor of human genetics and biostatistics at the ... School of Public Health , Zymo Research,s proprietary DNAge ™ technology ... ...
Breaking Medicine Technology: